Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jan-Feb;2(1):77-83.
doi: 10.4161/mabs.2.1.10786. Epub 2010 Jan 27.

Antibody fragments: hope and hype

Aaron L Nelson  1
Affiliations

Antibody fragments: hope and hype

Aaron L Nelson. MAbs. 2010 Jan-Feb.

Abstract

The antibody molecule is modular and separate domains can be extracted through biochemical or genetic means. It is clear from review of the literature that a wave of novel, antigen-specific molecular forms may soon enter clinical evaluation. This report examines the developmental histories of therapeutics derived from antigen-specific fragments of antibodies produced by recombinant processes. Three general types of fragments were observed, antigen-binding fragments (Fab), single chain variable fragments (scFv) and "third generation" (3G), each representing a successive wave of antibody fragment technology. In parallel, drug developers have explored multi-specificity and conjugation with exogenous functional moieties in all three fragment types. Despite high hopes and an active pipeline, enthusiasm for differentiating performance of fragments should, perhaps, be tempered as there are yet few data that suggest these molecules have distinct clinical properties due only to their size.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Antibody fragment types. Depiction of a full size antibody and various antibody fragment types. CH, constant heavy chain; CL, constant light chain; IgG, immunoglobulin; Fab, antigen binding fragment; scFv, single chain variable fragment, VH, variable heavy chain; VL, variable light chain. Source: Michael Hust, Technical University of Braunschweig. Figure used with permission.
Figure 2
Figure 2
Antibody probabilities of success. ‘Known fate’ is the percentage of candidates that were either FDA-approved or discontinued of those in a given cohort. Clinical phase transition probabilities were calculated as follows: the number of products that completed a given phase and entered the next was divided by the difference between the number of products that entered the phase and those that were still in the phase at the time of the calculation. Transitions occurring between phases of clinical studies conducted world-wide were included. The ‘cumulative rate’ is the percentage of FDA approved products of the total candidates with a known fate (FDA approved or discontinued).
See this image and copyright information in PMC

References

    1. Nelson AL, Reichert JM. Development trends for therapeutic antibody fragments. Nat Biotechnol. 2009;27:331–337. - PubMed
    1. Pappas DA, Bathon JM, Hanicq D, Yasothan U, Kirkpatrick P. Golimumab. Nat Rev Drug Discov. 2009;8:695–696. - PubMed
    1. Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 1992;52:3402–3408. - PubMed
    1. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 1990;50:814–819. - PubMed
    1. Cumber AJ, Ward ES, Winter G, Parnell GD, Wawrzynczak EJ. Comparative stabilities in vitro and in vivo of a recombinant mouse antibody FvCys fragment and a bisFvCys conjugate. J Immunol. 1992;149:120–126. - PubMed

MeSH terms